AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (8.19 g per portion at T1)
Number of subjects: 2286
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sugar consumption at T0 (8.27 g per 10 g)
Number of subjects: 2286
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pregnancy alcohol intake (15.32 g per g)
Number of subjects: 2286
Study 29373136 — intervention group
Group type: EXPERIMENTAL
Intervention: DyeVert™ system
Number of subjects: 96
Study 29373136 — intervention group
Group type: COMPARATOR
Intervention: Control (without DyeVert™ system)
Number of subjects: 96
Study 26509229 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×15 minutes application of 35% hydrogen peroxide gel
Number of subjects: 53
Study 26509229 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×15 minutes application of 35% hydrogen peroxide gel
Number of subjects: 53
Study 26509229 — intervention group
Group type: EXPERIMENTAL
Intervention: 3×15 minutes application of 35% hydrogen peroxide gel
Number of subjects: 53
Study 24149751 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO) group (n = 8) received verbal coaching cues, physical practice, and observed a video of a skilled model before performing each set.
Number of subjects: 15
Study 24149751 — intervention group
Group type: COMPARATOR
Intervention: Traditional Coaching (TC) group (n = 7) received standard coaching feedback (verbal cues and physical practice).
Number of subjects: 15
Study 23061541 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L tubular bandage
Number of subjects: 45
Study 23061541 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch compression bandage
Number of subjects: 45
Study 17660151 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted WHOQOL‐100 questionnaire
Number of subjects: 1068
Study 15613417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet incorporating 30% excess energy as fat
Number of subjects: 14
Study 15613417 — intervention group
Group type: COMPARATOR
Intervention: Energy-balanced diet
Number of subjects: 14
Study 11950108 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based intervention
Number of subjects: 1532
Study 11950108 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based intervention
Number of subjects: 1532
Study 11950108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined classroom- and peer-based intervention
Number of subjects: 1532
Study 11950108 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 1532
Study 10085475 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/cm2 melatonin applied 15 min before UV irradiation
Number of subjects: 20
Study 10085475 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 20
Study 8536413 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute leucocyte differential counts (cells x 10(9)/l)
Number of subjects: 0
Study 8536413 — intervention group
Group type: COMPARATOR
Intervention: Proportional leucocyte differential counts (percentage)
Number of subjects: 0
Study 1703769 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 85
Study 1703769 — intervention group
Group type: COMPARATOR
Intervention: CisEBP (cisplatin, bleomycin, etoposide, prednisone)
Number of subjects: 85
Study 1703769 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary CHOP treatment
Number of subjects: 85
Study 1703769 — intervention group
Group type: COMPARATOR
Intervention: Secondary CisEBP treatment
Number of subjects: 85
Study 1703769 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP arm
Number of subjects: 85
Study 1703769 — intervention group
Group type: COMPARATOR
Intervention: CisEBP arm
Number of subjects: 85
Study 420756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-complex supplementation
Number of subjects: 973
Study 420756 — intervention group
Group type: COMPARATOR
Intervention: Presence of clinical signs of vitamin B-complex deficiency
Number of subjects: 973
Study 31704508 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic flow consistent with treadmill speed
Number of subjects: 0
Study 31704508 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow sinusoidal modulation of the speed (SINE)
Number of subjects: 0
Study 31704508 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversals of optic flow velocity (REV)
Number of subjects: 0
Study 31704508 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study 31474260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed palatal crib (FPC) treatment (TG)
Number of subjects: 80
Study 31474260 — intervention group
Group type: COMPARATOR
Intervention: Nontreated (CG)
Number of subjects: 80
Study 27838097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 118
Study 27838097 — intervention group
Group type: COMPARATOR
Intervention: Participants with attenuated psychotic symptoms, first-degree relatives, and healthy controls
Number of subjects: 118
Study 27838097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia (after accounting for stress)
Number of subjects: 118
Study 25622825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trout raised on vegetable feeds
Number of subjects: 30
Study 25622825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trout raised on marine feeds
Number of subjects: 30
Study 25622825 — intervention group
Group type: COMPARATOR
Intervention: Chicken meal
Number of subjects: 30
Study 23356210 — intervention group
Group type: EXPERIMENTAL
Intervention: ASKP1240 (0.00003‐10 mg/kg)
Number of subjects: 72
Study 23356210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 21303799 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vaccination (day 4)
Number of subjects: 38
Study 21303799 — intervention group
Group type: EXPERIMENTAL
Intervention: Late vaccination (day 16)
Number of subjects: 38
Study 21303799 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 20137402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic anesthesia plus periprostatic nerve block (PNB)
Number of subjects: 120
Study 20137402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel plus PNB (Group C)
Number of subjects: 120
Study 20137402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic anesthesia plus PNB (Group D)
Number of subjects: 120
Study 20137402 — intervention group
Group type: COMPARATOR
Intervention: PNB alone (Group B)
Number of subjects: 120
Study 20137402 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (Group A)
Number of subjects: 120
Study 18196620 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg once daily
Number of subjects: 1482
Study 18196620 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg once daily
Number of subjects: 1482
Study 15071604 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab (30 mg i.v. TIW, 12 weeks)
Number of subjects: 21
Study 15071604 — intervention group
Group type: COMPARATOR
Intervention: observation
Number of subjects: 21
Study 15071604 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Number of subjects: 21
Study 12143454 — intervention group
Group type: EXPERIMENTAL
Intervention: One leg crossed over the other
Number of subjects: 90
Study 12143454 — intervention group
Group type: COMPARATOR
Intervention: Both feet flat on the floor
Number of subjects: 90
Study 11057002 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatible imagery condition (imagined passive self-motion in the same direction as target acceleration)
Number of subjects: 20
Study 11057002 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compatible imagery condition (imagined passive self-motion in the opposite direction to target acceleration)
Number of subjects: 20
Study 11057002 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (without imagery)
Number of subjects: 20
Study 9073051 — intervention group
Group type: EXPERIMENTAL
Intervention: ChlVPP
Number of subjects: 100
Study 9073051 — intervention group
Group type: COMPARATOR
Intervention: ChlVPP/ABOD
Number of subjects: 100
Study 1671346 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravenous metoprolol (15 mg IV over 6 minutes, followed by 50 mg orally every 12 hours for 24 hours, then 100 mg orally every 12 hours)
Number of subjects: 1434
Study 1671346 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravenous metoprolol
Number of subjects: 1434
Study 1671346 — intervention group
Group type: COMPARATOR
Intervention: Deferred metoprolol (50 mg orally twice on day 6, then 100 mg orally twice a day thereafter)
Number of subjects: 1434
Study 1671346 — intervention group
Group type: COMPARATOR
Intervention: Deferred metoprolol
Number of subjects: 1434
Study 6883915 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac (400 mg and 800 mg)
Number of subjects: 0
Study 6883915 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (15 mg and 30 mg)
Number of subjects: 0
Study 6883915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30285092 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength endurance training (40% one-repetition maximum)
Number of subjects: 100
Study 30285092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive strength training (80% of one-repetition maximum)
Number of subjects: 100
Study 30285092 — intervention group
Group type: COMPARATOR
Intervention: Control (stretching exercise)
Number of subjects: 100
Study 30292000 — intervention group
Group type: EXPERIMENTAL
Intervention: Staple line inversion (Group 1)
Number of subjects: 100
Study 30292000 — intervention group
Group type: COMPARATOR
Intervention: Staple line reinforcement with buttressing material (Group 2)
Number of subjects: 100
Study 26314234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiskal PRP
Number of subjects: 47
Study 26314234 — intervention group
Group type: COMPARATOR
Intervention: Control (contrast agent)
Number of subjects: 47
Study 23850254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 541
Study 23850254 — intervention group
Group type: COMPARATOR
Intervention: Radical nephrectomy (RN)
Number of subjects: 541
Study 22459201 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg of MDMA
Number of subjects: 58
Study 22459201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d‐methamphetamine
Number of subjects: 58
Study 22459201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20458441 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 80 mg
Number of subjects: 49
Study 20458441 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 49
Study 17122975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of virtual reality training and inanimate box training
Number of subjects: 65
Study 17122975 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training
Number of subjects: 65
Study 17122975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inanimate box training
Number of subjects: 65
Study 17122975 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 65
Study 16115831 — intervention group
Group type: EXPERIMENTAL
Intervention: Two intramuscular doses of 12 mg betamethasone in the 48 hours before delivery
Number of subjects: 998
Study 16115831 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 998
Study 11842389 — intervention group
Group type: EXPERIMENTAL
Intervention: FND (fludarabine/mitoxantrone/dexamethasone) plus rituximab
Number of subjects: 152
Study 10401895 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer team
Number of subjects: 0
Study 10401895 — intervention group
Group type: COMPARATOR
Intervention: Non-consumer team
Number of subjects: 0
Study 8640466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral hydration (sips of fruit juices sweetened with honey, solid food 24 hours later)
Number of subjects: 200
Study 8640466 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous hydration (2-3 L of dextrose saline/24 hours, solid food thereafter)
Number of subjects: 200
Study 8640466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral hydration
Number of subjects: 200
Study 2174277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platin
Number of subjects: 0
Study 2174277 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0
Study 2174277 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens including radiotherapy after chemotherapy
Number of subjects: 0
Study 30896987 — intervention group
Group type: EXPERIMENTAL
Intervention: DBN+SS laws
Number of subjects: 1441544
Study 30896987 — intervention group
Group type: COMPARATOR
Intervention: No DBN law
Number of subjects: 1441544
Study 30896987 — intervention group
Group type: COMPARATOR
Intervention: Generic DBN laws
Number of subjects: 1441544
Study 30056127 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 0.5% ropivacaine paravertebral block (PVB) with patient-controlled intravenous analgesia (PCIA)
Number of subjects: 114
Study 30056127 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 0.5% ropivacaine and dexmedetomidine (1 μg/kg) PVB with PCIA
Number of subjects: 114
Study 30056127 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative thoracic epidural anesthesia with 0.5% ropivacaine and single dose of epidural morphine (0.03 mg/kg) with PCIA
Number of subjects: 114
Study 27475714 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed‐chain and open‐chain exercises focusing on rotator cuff and scapulothoracic muscles for four weeks
Number of subjects: 36
Study 27475714 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 25250722 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulins (IVIG) treatment
Number of subjects: 18
Study 25250722 — intervention group
Group type: COMPARATOR
Intervention: Control IgG from healthy and diseased controls
Number of subjects: 18
Study 22708798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolaevulinate photodynamic therapy (PDT)
Number of subjects: 20
Study 22708798 — intervention group
Group type: COMPARATOR
Intervention: CO(2) laser ablation (LA)
Number of subjects: 20
Study 21698545 — intervention group
Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1 protein with ISCOMATRIX™ adjuvant (10 μg, 30 μg, or 100 μg)
Number of subjects: 28
Study 21698545 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg un‐adjuvanted NY‐ESO‐1 protein
Number of subjects: 28
Study 21698545 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg DTH protein
Number of subjects: 28
Study 21698545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21698545 — intervention group
Group type: EXPERIMENTAL
Intervention: DTH skin testing with NY‐ESO‐1 protein (1 μg) or peptides (10 μg)
Number of subjects: 28
Study 21698545 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-free survival
Number of subjects: 28
Study 21698545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour NY‐ESO‐1 or HLA class I
Number of subjects: 28
Study 17415632 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics as adjunct therapy to conventional treatment (corticosteroids and 5-aminosalycilic acid)
Number of subjects: 530
Study 17415632 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (short-term trials of 5-14 days)
Number of subjects: 530
Study 15667818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free phone tasks (artificial math operations)
Number of subjects: 0
Study 15667818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free phone tasks (emotionally involving conversation)
Number of subjects: 0
Study 15667818 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving tasks with greater demands
Number of subjects: 0
Study 15667818 — intervention group
Group type: EXPERIMENTAL
Intervention: Older drivers
Number of subjects: 0
Study 11898014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care with physical modalities
Number of subjects: 341
Study 11898014 — intervention group
Group type: COMPARATOR
Intervention: Chiropractic care without physical modalities
Number of subjects: 341
Study 10216089 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus 300 mg vitamin E twice daily (n = 9)
Number of subjects: 30
Study 10216089 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro vitamin E (50 micromol/L)
Number of subjects: 30
Study 10216089 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 5)
Number of subjects: 30
Study 8848526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretazenil (1 mg)
Number of subjects: 10
Study 2191890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vitamin E supplementation
Number of subjects: 0
Study 155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction, self-evaluation
Number of subjects: 27
Study 155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction, teacher-evaluation
Number of subjects: 27
Study 155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-aided instruction, self-evaluation
Number of subjects: 27
Study 155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-aided instruction, teacher-evaluation
Number of subjects: 27
Study 155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental lecture (given to half of each group)
Number of subjects: 27
Study 31090749 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural position (central group)
Number of subjects: 20
Study 31090749 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal position (palatal group)
Number of subjects: 20
Study 31090749 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study 28457318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4.4 g daily providing 2.6 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid)
Number of subjects: 80
Study 28457318 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 80
Study 26438703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional short messaging service (up to 3 personalized messages)
Number of subjects: 4587
Study 26438703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messaging service)
Number of subjects: 4587
Study 26438703 — intervention group
Group type: EXPERIMENTAL
Intervention: Response option '1' (clinic will call to schedule)
Number of subjects: 4587
Study 23934907 — intervention group
Group type: COMPARATOR
Intervention: Well-functioning implants
Number of subjects: 48
Study 23934907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-optimal functioning implants
Number of subjects: 48
Study 20647959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) users with CRP levels of 3 mg/L or higher
Number of subjects: 25991
Study 20647959 — intervention group
Group type: COMPARATOR
Intervention: Nonusers with CRP levels of 3 mg/L or higher
Number of subjects: 25991
Study 20647959 — intervention group
Group type: EXPERIMENTAL
Intervention: Logarithm CRP levels for HT users
Number of subjects: 25991
Study 20647959 — intervention group
Group type: COMPARATOR
Intervention: Logarithm CRP levels for HT nonusers
Number of subjects: 25991
Study 19662783 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (640 mcg of budesonide and 18 mcg of formoterol daily)
Number of subjects: 268
Study 16435613 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine
Number of subjects: 60
Study 16435613 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 60
Study 12938571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0
Study 10588996 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 23
Study 10588996 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn
Number of subjects: 23
Study 10588996 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 23
Study 8948369 — intervention group
Group type: COMPARATOR
Intervention: Nucleoside or non-nucleoside analog reverse transcriptase inhibitors
Number of subjects: 7
Study 8948369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nucleoside analog therapy
Number of subjects: 7
Study 8948369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (HIV protease inhibitor) monotherapy
Number of subjects: 7
Study 1755436 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration problems
Number of subjects: 2400
Study 1755436 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 2400
Study 1755436 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor achievement
Number of subjects: 2400
Study 6185222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (0.3-1.5 mg/kg bolus doses)
Number of subjects: 32
Study 6185222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (12-25 mg/h continuous infusion)
Number of subjects: 32
Study 6185222 — intervention group
Group type: COMPARATOR
Intervention: Tiapamil (1 mg/kg)
Number of subjects: 32
Study 6185222 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (0.13 mg/kg)
Number of subjects: 32
Study 29848343 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (Trauma‐focused Music and Imagery, TMI)
Number of subjects: 70
Study 29848343 — intervention group
Group type: COMPARATOR
Intervention: Verbal psychotherapy (standard treatment)
Number of subjects: 70
Study 28008004 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral pain intervention with goal agreement
Number of subjects: 122
Study 28008004 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral pain intervention with physically active goal agreement
Number of subjects: 122
Study 28008004 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered cognitive-behavioral pain intervention with no goal agreement
Number of subjects: 122
Study 25483830 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-month PA and F&V intervention
Number of subjects: 582
Study 23252601 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprevention intervention
Number of subjects: 471